Stroke, an important neurological disease, is becoming an increasingly non-communicable ailment and is the second leading cause of death after coroary heart disease in developed countries [1]. Present treatment options for stroke are adapting lifestyle practice, diabetes treatment, drugs, and other factors management, but no cure is yet available, despite new insights into the molecular and therapeutic targets.

Discoveries in explicating the molecular pharmacology in cerebrovascular function and thrombosis have led to significant advancements in the current treatment paradigm for patients with
stroke. Hence, this Special Issue invited scientific papers and reviews from researchers to provide solid evidence from a molecular point of view to scrutinize the molecular pharmacology and pathology
of strokes.

Platelet activation plays a major role in cardio and cerebrovascular diseases. Platelets also play a key role in the hemostatic process and are associated with various pathological events, such as arterial thrombosis and atherosclerosis. While currently used anti-platelet drugs such as aspirin and clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects.

Therefore, the development of effective therapeutic strategies for the prevention and treatment of thrombotic diseases is a demanding priority. Recently, precious metal drugs have conquered the subject of metal-based drugs, and several investigators have moved their attention to the synthesis of various ruthenium (Ru) and iridium (Ir) complexes due to their prospective therapeutic values.

ISBN 978-3-03897-541-0